Oncolytics Biotech Reports $9.2 Million Net Loss in Q1 2026, Increases R&D Spending

Oncolytics Biotech Inc. reported a net loss of $9.2 million for the first quarter of 2026, a significant increase from the $4.7 million loss recorded in the same period of the previous year. The company's total operating expenses rose to $9.3 million, up from $5.0 million in the first quarter of 2025, primarily driven by increased research and development (R&D) and general administrative costs. R&D expenses surged to $4.6 million, compared to $2.8 million a year earlier, reflecting higher personnel-related costs and expenses associated with the initiation of clinical trials. General and administrative expenses also increased to $4.7 million from $2.2 million, largely due to heightened public company-related activities and professional fees.

In terms of financial position, Oncolytics reported cash and cash equivalents of $5.5 million as of March 31, 2026, a slight increase from $5.2 million at the end of 2025. The company’s total assets grew to $8.2 million, up from $7.6 million, while total liabilities increased to $13.3 million from $11.4 million, resulting in a stockholders' deficit of $5.1 million compared to $3.8 million at the end of the previous year. The increase in liabilities was attributed to higher accrued liabilities and the reclassification of stock options from equity to liability due to a change in functional currency.

Strategically, Oncolytics has made significant advancements in its clinical development programs, particularly for its lead product, pelareorep. The company received Fast Track Designation from the FDA for pelareorep in combination with bevacizumab and FOLFIRI for treating second-line metastatic colorectal cancer. Additionally, a randomized Phase 2 study for this indication was launched in March 2026. The company is also exploring opportunities for registrational programs in other cancer types, including anal cancer and pancreatic cancer, supported by funding from the Pancreatic Cancer Action Network.

Operationally, Oncolytics has expanded its clinical trial activities and is actively seeking strategic partnerships to enhance its development capabilities. The company’s employee headcount has increased, contributing to higher personnel costs. As of March 31, 2026, Oncolytics had 116.1 million shares outstanding, reflecting a rise from 108.0 million shares at the end of 2025, following the issuance of shares through at-the-market offerings. The company plans to continue leveraging its equity distribution arrangements to support ongoing operations, although it acknowledges the need for additional financing to sustain its long-term development goals.

Looking ahead, Oncolytics Biotech Inc. anticipates continued operating losses as it advances pelareorep through clinical trials and incurs associated costs. The company is focused on securing additional capital to fund its operations and is exploring various financing options, including potential collaborations. Management has expressed confidence in the potential of pelareorep to enhance treatment outcomes for patients with gastrointestinal cancers, but acknowledges the inherent uncertainties and risks associated with drug development and regulatory approval processes.